drugset
drugset / Trial / NCT01121276

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

NCT01121276 ↗

Phase 1 Completed 82 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.

Timeline

Start
2010-04
Primary completion
2010-09
Completion
2010-09

Publications

  • Background Heise T, Haahr H, Jensen L, Ericsen L, Hompesch M. Faster-acting Insulin Aspart Improves Postprandial Glycemia vs Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM). Diabetes 2014; 63 ((Suppl 1)): A34 (abstract 129-OR)

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous

Indications

type 1 diabetes mellitus type 2 diabetes mellitus